Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (33)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Salvagno, L.
Right arrow Articles by Fiorentino, M. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salvagno, L.
Right arrow Articles by Fiorentino, M. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 3:833-837, 1992
© 1992 European Society for Medical Oncology

research-article

A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma

L. Salvagno1,, A. Contu2, A. Bianco1, L. Endrizzi3, G. M. Schintu2, N. Olmeo2, S. M. L. Aversa1, V. Chiarion-Sileni1, M. Sorarú1 and M. V. Fiorentino1

1Divisione di Oncologia Medica, Centro Oncologico Regionale Ospedale di Padova
2Servizio di Oncologia Medica Ospedale di Sassari
3Servizio di Oncologia Medica Ospedale di Bassano, Italy

Luigi Salvagno, MD Divisione di Oncologia Medica Centra Oncologico Regionale Ospedale di Padova 35100 Padova, Italy

From January 1988 to December 1991, 55 elderly patients (14 pretreated and 41 previously untreated) with non-Hodgkin's lymphoma (NHL) entered a prospective study to evaluate the feasibility of a combination of mitoxantrone (7–9 mg/m2), VP 16-213 (150 mg, 2-hour infusion on day 1, and 200 mg per os on days 3 and 5) and low-dose prednisone (25 mg days 1–5) (MVP regimen), recycling every 21–28 days. The median age was 75 (range 64–93). All but 4 pretreated patients had intermediate- or high-grade lymphomas. Complete remissions were obtained in 22 of 40 (55%) evaluable previously untreated patients, and partial remissions in 10 (2 of these obtained complete remissions after radiotherapy), for an overall response rate of 80%. The median duration of response was 12 months. At 24 months the overall survival was 52% and the relapse-free survival was 31%. Of 14 pretreated patients complete remissions were obtained in 4 (29%) and partial remissions in 3. Granulocytopenia and fever were the most important side effects; two patients contracted bronchopneumonia and one of them died. Other toxicities were mild. We conclude that this combination chemotherapy is effective as first-line and salvage treatment in elderly patients with intermediate- and highgrade NHL, and that it is feasible on an outpatient basis, with manageable toxicity.

non-Hodgkin's lymphoma, elderly patients, mitoxantrone etoposide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
S. Monfardini, S. M. L. Aversa, V. Zoli, L. Salvagno, A. Bianco, R. Bordonaro, G. Benevolo, M. Crugnola, G. Crivellari, P. Vivaldi, et al.
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
Ann. Onc., August 1, 2005; 16(8): 1352 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.K. Doorduijn, B. van der Holt, G.W. van Imhoff, K.G. van der Hem, M.H.H. Kramer, M.H.J. van Oers, G.J. Ossenkoppele, M.R. Schaafsma, L.F. Verdonck, G.E.G. Verhoef, et al.
CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 15, 2003; 21(16): 3041 - 3050.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. Zinzani, F. Gherlinzoni, S. Storti, A. Zaccaria, E. Pavone, L. Moretti, P. Gentilini, L. Guardigni, A. De Renzo, P. P. Fattori, et al.
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients
Ann. Onc., September 1, 2002; 13(9): 1364 - 1369.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. N. Mainwaring, D. Cunningham, W. Gregory, P. Hoskin, B. Hancock, A. J. Norton, K. MacLennan, P. Smith, G. V. Hudson, and D. Linch
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO
Blood, May 15, 2001; 97(10): 2991 - 2997.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. L. Zinzani, S. Storti, A. Zaccaria, L. Moretti, M. Magagnoli, E. Pavone, P. Gentilini, L. Guardigni, M. Gobbi, P. P. Fattori, et al.
Elderly Aggressive-Histology Non-Hodgkin's Lymphoma: First-Line VNCOP-B Regimen Experience on 350 Patients
Blood, July 1, 1999; 94(1): 33 - 38.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. L. Zinzani, E. Pavone, S. Storti, L. Moretti, P. P. Fattori, L. Guardigni, B. Falini, M. Gobbi, P. Gentilini, V. M. Lauta, et al.
Randomized Trial With or Without Granulocyte Colony-Stimulating Factor as Adjunct to Induction VNCOP-B Treatment of Elderly High-Grade Non-Hodgkin's Lymphoma
Blood, June 1, 1997; 89(11): 3974 - 3979.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.